ArticleFrontiers in medicine2026
Isolated gastrointestinal hereditary angioedema associated with a pathogenic
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a rare genetic disorder typically characterized by cutaneous and submucosal edema. Cases presenting exclusively with gastrointestinal symptoms, devoid of concurrent or historical cutaneous or upper airway manifestations, are uncommon. This atypical presentation poses a considerable diagnostic challenge and often leads to a marked delay in diagnosis, particularly in patients without a family history. We report the case of a 28-year-old female with an over 6-year history of recurrent, self-limiting abdominal pain. During a severe attack, abdominal computed tomography angiography (CTA) revealed jejunal wall edema and ascites, accompanied by a dramatic surge in D-dimer (>20.00 mg/L FEU) and fibrin degradation products (FDP >120.00 mg/L), closely mimicking mesenteric ischemia. However, a retrospective review of medical history identified the persistent consumption of complement C4 (0.03-0.05 g/L). Subsequent testing showed a functional C1 esterase inhibitor (fC1-INH) level of <7.0% and a C1 esterase inhibitor (C1-INH) antigen level of 6.81 μg/mL, confirming type 1 HAE. Whole-exome sequencing (WES) identified the nonsense variant NM_000062.3:c.990C>A, p.(Tyr330Ter), in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.